Radiopharmaceutical Therapy Centers of Excellence

SNMMI designated Centers of Excellence in Radiopharmaceutical Therapy meet strict regulatory, training, qualification, experience, and performance criteria to help assure patients, their families, referring physicians, and payors that rigorous procedures are in place and followed, leading to appropriate patient selection and outcomes from radiopharmaceutical therapy. We are currently accepting applications from centers based in the United States (its territories) and Canada.

Designated Clinical Centers of Excellence | Designated Comprehensive Centers of Excellence

Find an Designated Radiopharmaceutical Therapy Center of Excellence

Locate an SNMMI-designated Radiopharmaceutical Therapy Center of Excellence.

Educational Resources

Explore research articles and continuing education for radiopharmaceutical therapies, including recorded content from SNMMI meetings and webinars. More >>

Our Vision

Ensuring patients have reliable access to high quality radiopharmaceutical therapy, well-integrated into their pathway of care, delivered by highly qualified therapy teams, at technically qualified sites, and led by physicians appropriately trained in nuclear medicine acting as the patient’s “nuclear oncologist.”

  • Patients will be carefully evaluated for their suitability for radiopharmaceutical therapy, including in-person assessments in a clinical setting.
  • Treatment providers are suitably qualified by training, experience, and appropriate board certification, both to deliver the relevant radiopharmaceutical therapy and to use relevant imaging methods and equipment to assess patients before, during, and after radiopharmaceutical therapy. Providers must maintain CME.
  • Patients will have follow-up care with deep engagement of the treating physicians and/or the broader therapy team.
  • A team of experts, including nuclear medicine and molecular imaging, pathology, endocrinology, urology, social work, physics, and other relevant domain care exists.
  • Procedure frequency is sufficiently high in both relevant imaging methods and therapy procedures to assure continued excellence as evidenced by experience. (Clinical and Comprehensive Centers)
  • Sites have access to imaging with both PET/CT and SPECT/CT for all imageable therapeutic radionuclides used at the site. (Comprehensive Centers)
  • Dosimetry (if applicable) is performed with the engagement of a qualified medical dosimetry professional using methods that are standardized and validated. (Comprehensive Centers)
  • Sites are actively involved in radiopharmaceutical therapy research activities. (Comprehensive Centers)